Gastroenterology
Volume 137, Issue 1 , Pages 110-118 , July 2009

α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma

  • Jorge A. Marrero

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • Corresponding Author InformationReprint requests Address requests for reprints to: Jorge A. Marrero, MD, MS, University of Michigan, 3912 Taubman Center SPC 5362, Ann Arbor, Michigan 48109. fax: (734) 936-7392
    • ,
  • Ziding Feng

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Yinghui Wang

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Mindie H. Nguyen

      Affiliations

    • Stanford University, Palo Alto, California
    • ,
  • Alex S. Befeler

      Affiliations

    • Saint Louis University, St. Louis, Missouri
    • ,
  • Lewis R. Roberts

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • K. Rajender Reddy

      Affiliations

    • University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Denise Harnois

      Affiliations

    • Mayo Clinic, Jacksonville, Florida
    • ,
  • Josep M. Llovet

      Affiliations

    • Mt. Sinai Liver Cancer Program, Mt. Sinai University, New York, New York
    • BCLC Group, Liver Unit, Institució Catalana de Recerca i Estudis Avançats, IDIBAPS, CIBERehd, Hospital Clínic Barcelona, Barcelona, Spain
    • ,
  • Daniel Normolle

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • ,
  • Jackie Dalhgren

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • David Chia

      Affiliations

    • University of California, Los Angeles, Los Angeles, California
    • ,
  • Anna S. Lok

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • ,
  • Paul D. Wagner

      Affiliations

    • National Cancer Institute, Bethesda, Maryland
    • ,
  • Sudhir Srivastava

      Affiliations

    • University of California, Los Angeles, Los Angeles, California
    • ,
  • Myron Schwartz

      Affiliations

    • Mt. Sinai Liver Cancer Program, Mt. Sinai University, New York, New York

Received 8 December 2008 ,Accepted 2 April 2009.

References 

  1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARC Press; 2004;
  2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–S34
  3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–3044
  4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750
  6. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–1763
  7. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–S50
  8. Marrero JA, Hussain HK, Nghiem HV, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005;11:281–289
  9. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–1061
  10. Colli A, Fraquelli M, Conte D. Alpha-fetoprotein and hepatocellular carcinoma. Am J Gastroenterol. 2006;101:1939–1941
  11. Gupta S, Bent S, Kohlwes J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C (A systematic review and critical analysis). Ann Intern Med. 2003;139:46–50
  12. Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002;36:S84–S92
  13. Ono M, Ohta H, Ohhira M, et al. Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent γ-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-γ-carboxyprothrombin synthesis. Tumour Biol. 1990;11:319–326
  14. Shimauchi Y, Tanaka M, Kuromatsu R, et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive α-fetoprotein and des-γ-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep. 2000;7:249–256
  15. Marrero JA, Su GL, Wei W, et al. Des-γ carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–1121
  16. Ikoma J, Kaito M, Ishihara T, et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-γ-carboxy prothrombin: a prospective study. Hepatogastroenterology. 2002;49:235–238
  17. Ishii M, Gama H, Chida N, et al. South Tohoku District Study Group Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. Am J Gastroenterol. 2000;95:1036–1040
  18. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of α-fetoprotein. N Engl J Med. 1993;328:1802–1806
  19. Shiraki K, Takase K, Tameda Y, et al. A clinical study of lectin-reactive α-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology. 1995;22:802–807
  20. Wang SS, Lu RH, Lee FY, et al. Utility of lentil lectin affinity of α-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol. 1996;25:166–171
  21. Sterling RK, Jeffers L, Gordon F, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 2007;102:2196–2205
  22. Bruix J, Sherman M, Llovet JM, et al. European Association for the Study of the Liver Clinical management of hepatocellular carcinoma (Conclusions of the Barcelona-2000 EASL conference). J Hepatol. 2001;35:421–430
  23. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570–575
  24. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005;9:235–251
  25. Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep. 2008;10:60–66

 Conflicts of interest The authors disclose no conflicts.

 Funding Supported by Early Detection Research Network of the National Cancer Institute (CA-084986), by grant DK064909 (to J.A.M), and by test kits provided by Wako Diagnostics and Eisai.

PII: S0016-5085(09)00546-0

doi: 10.1053/j.gastro.2009.04.005

Gastroenterology
Volume 137, Issue 1 , Pages 110-118 , July 2009

Article Tools

* Image Usage & Resolution